16.64
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tarsus Pharmaceuticals Inc | TARS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 16.64 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.64 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 10.8001 - 30.9999 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 16.64 | USD |
Period:
Draw Mode:
Tarsus Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 443.60M | 26.66M | 19.75M | $ 57.03M | $ -13.83M | -0.72 | -6.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -345.33k | 5.80% |
Tarsus Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TARS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.87 | 19.66 | 16.11 | 17.80 | 75,496 | -1.23 | -6.88% |
| 1 Month | 15.32 | 19.66 | 14.06 | 16.50 | 73,220 | 1.32 | 8.62% |
| 3 Months | 14.44 | 19.66 | 12.27 | 14.70 | 149,006 | 2.20 | 15.24% |
| 6 Months | 15.80 | 20.82 | 10.8001 | 14.31 | 149,343 | 0.84 | 5.32% |
| 1 Year | 24.61 | 30.9999 | 10.8001 | 15.90 | 88,087 | -7.97 | -32.39% |
| 3 Years | 18.30 | 63.69 | 10.8001 | 22.85 | 78,761 | -1.66 | -9.07% |
| 5 Years | 18.30 | 63.69 | 10.8001 | 22.85 | 78,761 | -1.66 | -9.07% |
Tarsus Pharmaceuticals Description
| Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. |